Genetic instability in the tumor microenvironment: a new look at an old neighbor by Antonio Palumbo et al.
Palumbo et al. Molecular Cancer  (2015) 14:145 
DOI 10.1186/s12943-015-0409-yREVIEW Open AccessGenetic instability in the tumor
microenvironment: a new look at an old
neighbor
Antonio Palumbo Jr1,2*, Nathalia de Oliveira Meireles Da Costa2, Martin Hernan Bonamino2,3,
Luis Felipe Ribeiro Pinto2 and Luiz Eurico Nasciutti1*Abstract
The recent exponential increase in our knowledge of cellular and molecular mechanisms involved in carcinogenesis
has largely failed to translate into new therapies and clinical practices. This lack of success may result in part
from the fact that most studies focus on tumor cells as potential therapeutic targets and neglect the complex
microenvironment that undergoes profound changes during tumor development. Furthermore, an unfortunate
association of factors such as tumor genetic complexity, overestimation of biomarker and drug potentials, as
well as a poor understanding of tumor microenvironment in diagnosis and prognosis leads to the current
levels of treatment failure regarding a vast majority of cancer types. A growing body of evidence points to the
importance of the functional diversity of immune and structural cells during tumor development. In this sense,
the lack of technologies that would allow for molecular screening of individual stromal cell types poses a major
challenge for the development of therapies targeting the tumor microenvironment. Progress in microenvironment
genetic studies represents a formidable opportunity for the development of new selective drugs because stromal cells
have lower mutation rates than malignant cells, and should prove to be good targets for therapy.
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The incidence of cancer has increased worldwide over
the last century. In 2012, 32 million people had cancer
within 5 years of diagnosis, 14 million new cases were
diagnosed, and 8 million cancer deaths occurred world-
wide [1]. According to the World Health Organization
(WHO), within the next 15 years, over 17 million people
will develop cancer annually, and in 2030, cancer will
represent the leading cause of death worldwide, surpass-
ing cardiovascular diseases [2]. Thus, cancer not only af-
flicts individuals, but it has become a social problem
that burdens the public health systems which provide
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creativecommons.org/publicdomain/zero/1.0/During the past decades, an increasing body of work
has shed light on the cellular and molecular mechanisms
involved in the transformation of normal cells into can-
cerous cells. However, this research largely fails to im-
prove current clinical practices [3]. Physicians still treat
a vast majority of tumors using relatively old protocols
involving surgery, hormonal therapy, radio and chemo-
therapy [4]. New strategies including monoclonal anti-
bodies and tyrosine kinase inhibitors explore molecular
targets that are normally deregulated in cancer cells, and
represent a new hope for patients. However, these therap-
ies have only succeeded against a few types of cancers.
Carcinomas, for instance, often fail to respond to molecu-
lar target therapies [5, 6]. Unresponsiveness may result, at
least in part, because these therapies only target cancer
cells and neglect the complex microenvironment around
tumors that undergo drastic changes during disease devel-
opment [7]. Furthermore, neglecting these changes in
microenvironment cells could be a major oversight since,
lately, it has been shown that the alterations found inarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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the initiation of several tumors [8, 9]. In this way, tumor
microenvironment cells could represent an extremely at-
tractive therapeutic target either along the course of the
disease or during the first steps of malignant
transformation.
Reciprocal cellular interactions
Cellular interactions lie at the core of metazoan physi-
ology and encompass an effective and elegant signaling
repertoire that integrates up to trillions of cells in a sin-
gle organism. These interactions begin during the early
stages of embryonic development and coordinate events
such as cell proliferation and differentiation in complex
tissues, crucial processes for the functional maintenance
of whole organs [10]. During adult life, tissue homeosta-
sis is supported by direct cellular interactions and by the
continuous exchange of soluble and non-soluble factors
released by different cellular compartments [11].
Cell-cell interactions primarily occur between the
mesoderm, endoderm and ectoderm during embryonic
development and between the parenchyma and stromal
compartments throughout adult life [12, 13]. In a vast
majority of organs, distinct epithelial tissues form the
parenchyma, whereas the stroma constitutes a complex
compartment composed of different cell types including
fibroblasts and myofibroblasts, vessel cells, pericytes,
endothelial and smooth muscle cells, as well as immune
cells such as macrophages, lymphocytes and mast
cells. Finally, these different cell types are immersed in
a complex protein network named extracellular matrix
(ECM) [14].
Cellular interactions in the tumor microenvironment
Carcinomas, which by definition arise from epithelial cells,
account for nearly 80 % of all human cancers [1]. Epithe-
lial cell transformation disturbs tissue homeostasis, but
also causes extensive changes to the microenvironment
surrounding the developing tumor [15–17]. Thus, the
imbalance in homeostasis induced by cancer cells also
promotes aberrant cellular behavior in the stroma, cul-
minating in the complete alteration of reciprocal interac-
tions mediated by this compartment [18]. This altered
microenvironment, also known as reactive stroma, is
histopathologically characterized by extensive phenotypic
modifications, such as ECM remodeling, loss of smooth
muscle cells, and persistent infiltration by myofibroblasts,
as observed in a prostate cancer model [19].
Reactive stroma has been shown to emerge at the begin-
ning of the disruption of the interactions with the epithe-
lial compartment along prostate malignant transformation
[20] and seems to be crucial to support the early steps of
tumor progression in several tissues such as breast, ovary
and liver [20–23]. A pivotal role in the generation of thereactive stroma is played by the Transforming Growth
Factor β (TGF-β), which triggers the cell phenotype
changes that characterize this compartment [20].
The TGF-ß superfamily is composed by different growth
factors which play important roles in both physiological
and pathological processes and, lately, has been associated
with cancer development [24]. TGF- ß has dual functions
in the cell, acting as tumor suppressor and oncogene. Even
though in normal development TGF-ß acts as a differenti-
ation and anti-proliferation factor in distinct cell types
[25], in cancer, it leads to loss of cellular growth inhibition,
proliferation activity, metastasis, angiogenesis, invasion
and migration, favoring epithelial-mesenchyme transition
(EMT) [25–27]. Under TGF-β influence, the stromal tis-
sue, which is originally composed of a large amount of
smooth muscle cells and molecular characterized by the
expression of muscular differentiation proteins such as
desmin, calponin, as well as myosin heavy chain, becomes
more fibrous, displaying increased number of myofibro-
blasts, loss of muscular differentiation markers expression,
along with an augmentation in the presence of the fibrous
marker α smooth muscle actin [28]. The stromal pheno-
type change also induces ECM remodeling, resulting in
the release of new growth factors and ECM molecules,
such as collagen I and III [29], tenascin C and versican
[30, 31], besides matrix metalloproteinases (MMP) 2 and
9 [32]. In addition, TGF-β inhibition was demonstrated to
decrease the formation of new blood vessels in xenograft
prostate cancer model [33], as well as apoptosis rates of
prostatic myofibroblasts [34]. Besides TGF-β ability to
promote ECM remodeling and, consequently, the release
of angiogenic factors such as vascular endothelial growth
factor (VEGF) [35], its angiogenic role also occurs through
the boosted expression and release of angiogenic pro-
moters such as Connective-Tissue Growth Factor (CTGF)
and Fibroblast Growth Factor 2 (FGF-2) [36, 37]. More-
over, TGF-β directly regulates the expression of these two
growth factors during the healing process where they are
found involved with proliferation and migration signaling
stimulus sent to fibroblasts, epithelial and endothelial cells
[38]. These data reinforce the perspective that the alter-
ations observed in the reactive stroma consist in a reedi-
tion of the mechanisms usually involved in the healing
process [39], nevertheless, instead of arising from a spe-
cific biological context, the molecules controlling this
response are constantly produced by the altered react-
ive stroma, thus contributing to promote important
cancer hallmarks such as angiogenesis [40], invasion [41],
metastasis [42] and the EMT [43].
The EMT seems to represent a breakpoint in enabling
malignant cells to invade other tissues and organs. In
fact, the EMT is primarily a cellular biological program
typically involved in various stages of embryonic mor-
phogenesis and wound healing, however, the wide
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process is also used as a subterfuge by transformed cells
to acquire skills related with invasion, metastasis and re-
sistance to apoptosis [44]. This process is characterized
by the transition from an epithelial and weak migratory
phenotype to an intense migratory phenotype related
with cells from mesenchyme origin, such as fibroblast
cells [45]. One of the main characteristics of EMT is the
repression of E-cadherin expression, which occurs
through its regulation by several transcription factors in-
cluding Snail, Slug, Twist and Zinc Finger E-Box Binding
Homeobox (Zeb) 1/2. These transcription factors are
also associated with matrix metalloproteinases expres-
sion and release that ultimately leads to an increase in
cell motility and resistance to apoptosis [44]. In fact, the
adherents junctions destabilization by E-cadherin repres-
sion is frequently observed in most of carcinomas [46].
Given the importance of the epithelial apical junctional in-
tegrity mediated by E-cadherin, its repression in malignant
cells represents a crucial event that culminates in loss of
adhesion between these cells and in enabling the cellular
escape from its original site, which speak for the initial
steps of tumor progression [47]. Nonetheless, recent stud-
ies have shown that E-cadherin loss is not sufficient to dir-
ect the EMT process in a mammary carcinogenesis
model, since the initial events of cytoskeleton
organization were architecture despite its expression
absence [48, 49]. On the other hand, while genes related
with growth inhibition and cell proliferation are typically
downregulated in EMT, genes coding adhesion proteins
normally associated with cellular migration during the
embryogenesis and inflammation are found upregulated
during this process [50], particularly N-cadherin and
genes belonging to immunoglobulin superfamily [50,
51].
In this complex scenario represented by cellular inter-
actions between stromal and epithelial cells, Weinberg
and colleagues elegantly clarified these interplay during
disease progression in two reports. In a study using in vitro
and in vivo approaches, these authors showed that trans-
formation of human mammary epithelial cells mediated by
transfection with HRAS and hTERT increased cell prolifer-
ation and survival in vitro. Nude mice inoculated with these
cells and mammary fibroblasts grew tumors twice as fast as
mice inoculated with transformed cells alone [52]. This
seminal work represented one of the first to show that
genetic transformation per se does not confer all of the
malignant characteristics observed in tumor cells, in
particular those related with cellular invasion [53],
epithelial-mesenchyme transition [54] and metastasis
[55, 56]. In a subsequent study, the same group re-
ported that fibroblasts derived from mammary tumors
promoted malignant growth by locally inducing angio-
genesis through the secretion of Stromal Derived Factor1 (SDF-1), which attracts endothelial progenitor cells
from the bone marrow [57]. However, in the same study
it was noted that tumor growth was also supported in the
presence of artificial ECM matrigel, even in the absence of
fibroblasts. In fact, this could be partially explained by the
well established role of ECM as a growth and angiogenic
factors reservoir [58]. Furthermore, it had been previously
demonstrated that ECM was able to modulate the ex-
pression of genes involved with malignant phenotype
acquisition [16].
Since then, many studies have demonstrated the im-
portance of the microenvironment in tumor progression.
Recently, Maxwell and colleagues demonstrated that the
release of the chemokine (C-X-C motif) ligand (CXCL)-8
in PTEN (phosphatase and tensin homolog deleted on
chromosome 10) depleted prostate cancer cells up reg-
ulated the expression of chemokine receptors chemo-
kine (C-X-C motif ) receptors (CXCR) 1, 2 and 4 in the
stromal compartment, besides augmenting the release
of CXCL-12 and chemokine (C-C motif ) ligand (CCL)2
that, in turn, by a paracrine signaling, sustained the ag-
gressive behavior exhibited by malignant prostate cells
[59]. The tumor suppressor gene PTEN controls cell sur-
vival and proliferation through the inhibition of PI3K/Akt
intracellular signaling pathway [60]. PTEN is constitutively
expressed in cells and figures as one of the genes most fre-
quently mutated in several distinct tumors, demonstrating
its importance in physiological processes [61]. The study
published by Maxwell and colleagues shows that altered
inflammatory chemokines release mediated by the loss of
an important tumor suppressor as PTEN, represent an
important axis in the interaction between stromal and
malignant cells [62, 63].
In fact, the link between inflammation, cancer develop-
ment and progression, first proposed by Virchow, is now a
widely recognized process [64] currently described in
details for several different tumors, including carcinomas
of different origins [65–67]. Inflammatory components
found in the tumor microenvironment such as macro-
phages, neutrophils, basophils, lymphocytes and other
cell subsets establish interactions and crosstalk within the
leukocyte compartment and with tumor cells orchestrat-
ing tumor progression and invasiveness.
The simple presence of leukocytes in the tumor mass
does not allow discriminating the role these cells are
playing in the tumor microenvironment. Leucocyte sub-
sets can display different functions (CD4 T helper 1, 2,
17, regulatory T cells, CD8 cytotoxic T cells, regulatory
B cells, immunosupressive myeloid derived suppressor
cells –MDSCs- and others). Macrophages, for instance,
display a full spectrum of functions that allow them to
perform different tasks in the tumor microenvironment.
These cells have been classically classified as M1 or M2
[68]. Macrophages classified as M1 are associated to
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tumor responses related to tumor vessels. These cells
are related to type I interferon responses and reactive oxy-
gen species burst. On the other hand, M2 macrophages
are related to scavenger functions, IL-10 and arginase pro-
duction, amongst other characteristics [69]. Macrophage
polarization is closely related to functional polarization
of other cell subsets, such as helper lymphocytes (Ths).
Classic M1 cells are associated to Th1 (IFNg secreting)
cells, while M2 cells correlate to Th2 (IL-4 and Il-13
secreting) cells, indicating a more complex and coordi-
nated program that orchestrates more than one leukocyte
subpopulation. Linked to IFNg producing Th1 cells,
CD8+ effector lymphocytes can eliminate tumor cells
and help to establish an anti-tumor microenvironment.
Other immune subpopulations have been described as
playing roles in tumor progression, such as neutrophils
(displaying the N1 and N2 polarization in cancer [70],
recapitulating macrophages M1 and M2 status) and B
lymphocytes [71, 72]. For some epithelial tumors, members
of the innate and adaptive immunity seem to act coordi-
nately promoting tumor progression. These networks
include circuits described in mouse models recapitulat-
ing progressive spontaneous tumors. As examples, some
recent descriptions include the mammary tumor cell-
M2 macrophage and Th2 lymphocytes interplay in the
MMTV-PyMT transgenic mouse breast cancer model
[73] or the tumor cell - B lymphocyte activation and
myeloid cell activation loop based on immunoglobulins
and FcR interactions fostering squamous cell carcinoma
progression in the K14-HPV16 mouse model [71].
Tumor cells not only recruit leukocytes to the tumor
mass through chemokines (such as CSF-1) but are also
stimulated by growth factors produced by the leukocytes
(such as EGF produced by macrophages [74] and also
modulate the function of these infiltrating tumor cells
through the production of several immune modulators
such as indoleamine 2,3-dioxygenase (IDO), TGF-β, Inter-
leukin (IL)-10, arginase [75] or even lactate, as a result of
the Warburg effect on tumor cell metabolism [76].
Taking into account the interplay of different leukocyte
populations in the tumor, some groups are simplifying
the evaluation of the complexity of tumor microenviron-
ment by assuming correlations such as the ratio of CD4/
CD8/CD68 (macrophage marker) in human tumors to
estimate Th1/cytotoxic based responses and macro-
phages presumed to be M1 (if CD8/CD68 ratio is high),
or M2 (if the ratio is low) [73].
Other groups take into account not only the function
of the cells in the tumor microenvironment, but also dif-
ferent cell localizations, considering the relevance of the
capacity of the cells to invade the tumor mass or to stay
at the tumor margin [77, 78]. This approach has been
named the Immunoscore, and represents a multi-centereffort to demonstrate the predictive value of immune
architecture evaluation in tumor samples. This approach
is under extensive validation for some tumors such as
colon adenocarcinomas [79] and highlights the relevance
of characterizing the immune functions in the tumor
biology field of study.
The immune architecture is not only a function of the
immune cells recruited to the tumor site, but also of the
intrinsic characteristics of tumor cells. As already men-
tioned, signaling loops have been extensively described
between the tumor cells and immune system cellular
components [66, 67, 71]. Nonetheless the activation sta-
tus of components of the immune system have been as-
sociated with genotoxicity to tumor cells due to local
production of reactive oxygen and nitrogen species [80]
or the activation of mutation inducing machineries such
as Recombination Activating Gene (RAG), Activation-
induced Cytidine Deaminase (AID) [81] or Apolipoprotein
B mRNA Editing Enzyme, Catalytic Polypeptide-Like
(APOBEC) proteins [82].
In addition, it has already been reported that blood
and lymph vessels network development also represents
a notorious hallmark during carcinogenesis and tumor
progression [44]. The peculiar nature of tumor vascula-
ture not only provides the required conditions to malig-
nant cells survival, spread and metastasize, but also creates
a protective niche to tumor cells during disease develop-
ment and treatment [83]. Inefficient lymph vessels drainage
along with immaturity of tumor vessels creates a heteroge-
neous scenario mainly represented by hypoxia areas and
variations in the interstitial pressure [83], that ultimately
impacts in tumor progression and resistance to treatment
[84, 85]. In this way, as key players in vessels development,
the endothelial cells posses a prominent role in the disease
[86]. In fact, the role of endothelium is not restricted to
angiogenesis and vasculogenesis. Recent studies have re-
ported that E-selectin expression in addition to EGF and
IL-6 release by endothelial cells respectively mediates me-
tastasis, EMTand cancer stem cells expansion [87–89].
Finally, the microenvironment has been implicated not
only in tumor progression but also in carcinogenesis.
Some clues initially originated at the end of the 1990s
specifically associated MMP-3 expression and release with
the development of breast cancer [90, 91]. Further, the
authors dissected the mechanisms involved in the
phenomenon by showing that MMP-3, which is nor-
mally overexpressed in breast tumor stroma [92], was
capable of mediating the malignant epithelial transform-
ation by inducing Rac1b expression. The increment of
Rac1b expression increases ROS level that, in turn, pro-
duces DNA damage and genomic instability, besides pro-
moting EMT activation by stimulating the expression of
the transcription factor Snail [93]. Furthermore, additional
researches have reinforced this perspective by showing
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an stealthy found, but a solid paradigm change in the
carcinogenesis field [94–96].
Genetic alterations in the tumor microenvironment
Since genes were identified as key elements in the car-
cinogenic process, they have become the focus of many
cancer research projects. These studies have contributed
to our knowledge of genetic alterations involved in disease
generation and progression, including polymorphisms,
mutations, translocations, recombination, and the regu-
lation of gene expression. Moreover, this body of work
has allowed for the development of tools currently used
in disease diagnosis, prognosis and treatment [97]. The
recent advent of large scale analysis techniques enabled
researchers to investigate not only small sets of genes,
but entire eukaryotic cell genomes. Such studies have
contributed to the mapping of hundreds of genes asso-
ciated with signaling pathways involved in cancer [98].
Large scale analyses, such as gene expression microar-
rays, have elucidated the gene expression signatures of
many types of cancer, mostly carcinomas [99].
Unveiling the molecular constitution of tumors also
revealed major differences in gene expression patterns of
stroma surrounding normal and cancer tissues. For ex-
ample, breast carcinoma associated fibroblasts (CAF),
when compared to normal breast tissue fibroblasts, alter
the expression of genes, in particular those associated
with the healing process, such as PLAUR, LOXL2, PLOD2
and SDFR1 [100]. Analyses of solitary fibrous tumor (SFT)
compared to desmoid type fibromatosis (DTF) revealed
significant differences in stromal molecular profiles. The
STF expression pattern correlated with decreased survival
rates as a consequence of enriched expression of genes re-
lated with ECM remodeling, such as Collagen Type I and
Type III and MMPs 11, 9 and 23; proliferation genes in-
cluding Fibroblast Growth Factor (FGF), WNT5A, FZD 1
and 2; as well as angiogenic promoters such as TGF-β and
CTGF [101]. On the other hand, DTF stromal gene ex-
pression correlated with better prognosis and overall sur-
vival not only for breast cancer, but also for ovarian, lung
and colon tumors [102]. In vitro studies provided further
evidence of the consequences of altered genetic expression
in breast stromal cells: in co-cultures, up-regulation of
CCL18 and CCL2 in CAF promoted breast tumor pro-
gression by inducing cellular invasion [103].
Large scale gene expression analyses performed in pros-
tate tumors demonstrated that approximately 500 genes
were up-regulated and 600 genes were down-regulated in
tumor stroma [104]. Most differentially expressed genes
participate in cancer-associated pathways, including the
apoptosis pathway genes FOXL2, STAT1 and PPARγ; cell
proliferation genes NOTCH1 and C-KIT; and DNA repair
genes MRE11A, HUS1 and RAD17. Moreover, the sametumor stroma overexpressed Epidermal Growth Factor
(EGF), FGF, TGF-β, Wnt and ECM related genes (Fig. 1),
all of which participate in processes that ultimately disrupt
interactions mediated by stroma during prostate cancer
progression [105–107].
More recent work utilized the same approach to iden-
tify molecular alterations during the progression of
esophageal adenocarcinoma. The authors reported that
stromal samples from Barrett’s esophagus, a clinical
condition caused by the long-term gastroesophageal re-
flux disease (GERD) that normally precedes the esopha-
geal adenocarcinoma development, exhibits a peculiar
inflammatory gene expression pattern, mainly represented
by the TGF-β pathway. On the other hand, adenocarcin-
oma stromal samples overexpressed genes associated with
poor prognosis including TMEPA, Thrombospondin 1,
and BCL6 [108]. In this way, the authors conclude that
esophageal stromal compartment presents a distinct gene
expression signature, along the pathological steps involved
in the disease progression.
In functional studies conducted in vitro comparing fi-
broblasts from normal human lungs and from non-small
cell lung-cancer, the latter overexpressed genes involved
in the TGF-β and MAPK signaling pathways. These find-
ings were corroborated by parallel ex-vivo analyses of
fresh tissue samples, and activation of the signaling path-
ways correlated with a worse prognosis [109]. Ovarian
[110] and colon carcinomas [111] also display extensive
stromal alterations. In addition to the effects of broad
gene expression changes in the tumor microenvironment,
a critical point for disease progression resides in the status
of the master gene Tumor Protein p53 (TP53). Many
studies have extensively explored the roles of TP53 in
tumor cells [112–114]. More recent work, however, has
focused on the loss of functional TP53 in the stroma of
different tumor types [115–119].
In this way, data produced by Hill and colleagues
showed that conditional deletion of Rb gene in mice epi-
thelial cells not only allows tumor formation by prostate
cells, but also leads to the loss of TP53 in the stromal
compartment, abrogating the homeostasis between epi-
thelial and stromal tissues and ending up with loss of
TP53 also in the tumor [118]. These observations raised
the hypothesis that the well reported loss of TP53 in
most of human carcinomas could be preceded by TP53
loss in stromal cells which, in turn, would happen as a
consequence of an initial driver genetic event in epithe-
lial tissue, such as Rb gene loss, responsible for not only
promoting a permissive microenvironment propitious to
initiated cells, but also for contributing to an important
event in tumor progression which is TP53 loss. A pro-
vocative hypothesis conjectured by Hill and colleagues
suggested that oncogenic stress mediated by initiated
epithelium would create a selective pressure in the
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Fig. 1 Molecular alterations found in the tumor microenvironment (ME) and the role of stromal cells in therapy resistance and disease recurrence.
Upper panel: different steps comprised between initial therapeutic approach and tumor recurrence. 1 Tumor and ME cells at the beginning of
selective drug therapy. 2 The selective pressure imposed by treatment contributes to the acquisition of secondary tumor mutations and genetic
alterations in ME cells, which in turn affect tumor cells. ME alterations are represented in the CAF cell shown in the lower panel. Most of these
alterations are associated with the loss of expression of tumor suppressor genes, such as PTEN and APC, which leads to increased tumor survival
and proliferation. Furthermore, the loss of TP53 expression observed in CAF increases ENOS activity, which culminates in an elevation of reactive
nitrogen species (RNS) and the consequent transformation of the epithelial tissue surrounding the tumor. Moreover, the higher expression of
growth factors (e.g., VEGF, PDGF and HGF) contributes to tumor growth and invasion, while TGF-β down-regulation decreases the expression of
CDK inhibitors (p15, p16 and p21) in tumor cells, leading to tumor proliferation and survival. On the other hand, TGF-β up-regulation increases
the expression of genes related with extracellular matrix (ECM) remodeling (Col I, Col III, MMP 9, MMP 11 and MMP23) which directly contribute
to tumor progression. 3 ME cellular alterations, in addition to the recruitment of immune cells, and the increase in ME inflammation create a protective
niche that results in therapy resistance. 4 The final outcome: tumor re-growth and disease recurrence
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stromal cells selection [118]. Of note, this hypothesis was
later partially corroborated by a study which showed that
in breast and lung xenograft cancer models the number of
malignant cells impacts on the oncogenic stress intensity
that, in turn, induces the selection of p53deficient stro-
mal cells [120]. The study of Farmaki and colleagues pro-
posed that the large amounts of growth factors produced
by malignant cells, such as EGF, creates a mitogenic stress
that impairs the proliferation of p53-wild type fibroblasts,
nevertheless, this stimulus is ineffective to p53-deficient fi-
broblasts, that are consequently selected in the tumor
microenvironment [120]. A crucial limitation that could
compromise the interpretation of the data achieved in the
above cited studies is the joint inoculation of p53-wild
type and p53-deficient fibroblasts. In this way, the data
produced by Farmaki and colleagues not efficiently clari-
fied if the intrinsic selective advantage provided by TP53absence was achieved due to the selective pressure im-
posed by malignant cells through oncogenic stress or due
to the presence of p53-deficient fibroblasts since the be-
ginning of the process. Despite the fact that the precise
mechanisms of TP53 loss in stromal cells had not been
elucidate, the oncogenic stimulus emerges as a pivotal
player in this process, since classical molecular alterations
in the epithelial compartment, such as k-Ras mutation,
were reported as sufficient to inhibit TP53 expression in
the fibroblasts [121].
Alternatively, the consequence of TP53 loss in stromal
cells has been particularly implicated in tumor progres-
sion, once its absence is inversely proportional to SDF-1
cytokine levels that, in turn, are involved with cellular
proliferation and migration stimulus [122]. In fact, it was
previously demonstrated that TP53 overexpression in fi-
broblasts leads to a down-regulation of SDF-1 and con-
sequently attenuate migration and invasiveness processes
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angiogenesis by stimulating the recruitment of endothelial
progenitor cells [57]. Furthermore, homeostasis disruption
promoted by TP53 loss in the microenvironment cells is
also apparently involved with alterations in the cellular
redox state. During in vitro assays, stable silencing of
TP53 in fibroblasts resulted in overexpression of Endothe-
lial Nitric Oxide Synthase (eNOS) (Fig. 1). Subsequently,
reactive nitrogen species accumulation produces an unbal-
anced redox state, a well-known phenomenon related with
alterations in the expression and function of many pro-
teins [124]. The redox unbalance produced by TP53 loss
in fibroblasts cells, was strikingly related with an increase
in mRNA and protein expression on Cytokine Intercellu-
lar Adhesion Molecule 1 (ICAM1), as well as in its incre-
mented release. Moreover, these alterations culminated in
the transformation and invasion of epithelial cells from
the ovaries and oral cavity [125].
In fact, oxidative stress damages DNA in tumor cells,
but also in stromal cells, contributing to an even greater
disruption of microenvironment homeostasis during tumor
progression [126, 127]. Moreover, the importance of TP53
status in microenvironment was reinforced by the ob-
servation that the melanoma cell line B16F1 inoculated
in p53-null mice produces tumors greatly faster than
p53-wild type mice [63]. Increased amount of myeloid
derived suppressor cells and leukocytes together with
decreased number of CD8 lymphocytes was observed in
tumors originated in animals lacking TP53. This scenario
propitiated tumor growth by promoting an immunoto-
lerant and permissive microenvironment which was ev-
idenced by IFN-γ- and IL-17A suppression. In addition,
the exacerbated release of G-CSF, CXCL1 and IL-6 che-
mokines creates an inflammatory context that promotes
malignant proliferation and cell spread by sustaining
the angiogenesis process [63].
In addition to TP53, the loss of function of other tumor
suppressor genes in tumor stroma has severe conse-
quences. For example, studies report that loss of function
of genes involved in cell survival and proliferation, such as
the APC (Adenomatous Polyposis Coli) and PTEN genes
(Fig. 1), strongly contributes to endometrial and breast
cancer development, respectively. APC deletion was asso-
ciated with the development of an advanced malignant
phenotype represented by myofibroblast infiltration, re-
lease of angiogenic factor promoters, including VEGF and
SDF, and a decrease in responsiveness to progesterone
and estradiol via reduction of receptor expression [128].
APC gene is a tumor suppressor mostly known by nega-
tively regulating the Wnt/ß-catenin pathway, nevertheless,
it controls many other cellular functions such as migra-
tion, regulation of apical-basal polarity, microtubule
networks, cell cycle, DNA replication and repair andapoptosis that are involved in the organization of epi-
thelial tissues [126, 127, 129].
On the other hand, PTEN loss results in Ets2 overex-
pression and activation, which in turn promotes immune
cell infiltration and angiogenesis, as well as ECM remod-
eling [130, 131]. Ets2 belongs to the Ets (E26
transformation-specific) transcription factor family,
which comprises approximately 30 evolutionary con-
served members that are frequently found deregulated in
cancer [132–134]. Ets2 overexpression has already been
demonstrated to stimulate cell proliferation and tumor
progression [135, 136].
In other hand, as previously reported, TGF-β repre-
sents an important frequently altered gene in the tumor
microenvironment. This growth factor acts as a general
coordinator of microenvironment homeostasis in most
types of tumors, [137] and its signaling pathway is nor-
mally activated in most tumor stromal compartments
[101, 108]. On the contrary, the absence of TGF-β path-
way activation also figures as a critical event in some sit-
uations, specifically when its signaling pathway disruption
is mediated by the lack of Transforming Growth Factor
Beta Receptor II (TGFBR2), as observed in colon and
esophageal carcinomas [138, 139]. Particularly in esopha-
geal squamous cell carcinoma, deletion of TGFBR2 in
mouse fibroblasts in vivo resulted in extensive genetic and
epigenetic alterations, such as loss of cyclin inhibitors p15
and p16, as well as hypermethylation of the p21WAF1
promoter in surrounding epithelial cells (Fig. 1) that ul-
timately developed into esophageal squamous cells car-
cinomas [139].
On the other hand, genetic lesions in the tumor cells
have also been described to influence the characteristics
of the leukocytes infiltrating the tumor mass. For in-
stance, some genetic deletions comprising regions bear-
ing leucocyte stimulating factors can be deleted leading
to poor local lymphocyte proliferation, as shown for the
IL-15 deletion in colorectal tumors [140]. In this case,
the limited expansion of lymphocytes leads to impaired
anti-tumor responses, assuring constant tumor growth.
Genetic deletions of regions including other immune
mediator have been described in some tumors, such as
IFNg locus deletions in melanomas [141], although the
relevance of these events in terms of tumor immune
architecture is still to be determined.
Alternatively, genetic studies on tumor microenviron-
ment have shown that, despite the important changes
observed in gene expression in a wide range of tumors,
[128, 131, 142–145] this compartment is normally genet-
ically more stable than epithelial tissues, exhibiting low
mutation rates [146, 147]. Taking advantage of a SNP array
platform, Qiu and colleagues showed that CAFs derived
from ovarian and breast cancer rarely exhibit alterations
in gene copy number and LOH [146]. This observation
Palumbo et al. Molecular Cancer  (2015) 14:145 Page 8 of 15launched the discussion on whether the majority of the
genetic alterations mapped in tumor microenvironment
could be a result of the limitations of the techniques
employed in the diverse studies. In the same study, this
question was elegantly raised by authors due to the ob-
servation that when a fraction of DNA derived from
tumor epithelial cells was combined with normal DNA,
all the major alterations previously mapped in the tumor
sample were also detected in the mixed sample, suggesting
that a simple tissue contamination would be sufficient to
mask the results. In fact, some studies reported a high fre-
quency of genetic alterations in tumor microenvironment
cells. In some cases, the alteration load was comparable to
that observed in epithelial cells, with LOH frequency near
60 % in CAFs derived from ovarian and breast cancer
[143, 145], supporting the idea that sample contamination
and technical limitations could account for the surprising
results achieved. Tissue microdissection and in vitro cell
segregation were presented as possible alternatives for the
technical issues faced. Nevertheless, Alinen and colleagues
published an interesting study in which was demonstrated
that all breast cancer cell types exhibited changes in
gene expression, however, genetic alterations were only
detected in malignant cells [148].
Further, a similar study corroborated the results pro-
duced by Alinen and colleagues and reported that only
one sample, out of 25 CAFs obtained from 25 fresh
breast samples, exhibited a chromosomal aberration in-
volving the chromosomes 4, 6 and 9 and another one a
TP53 point mutation [147]. In addition, the role played
by epigenetic alterations in controlling the gene expres-
sion changes exhibited by microenvironment cells defini-
tively cannot be excluded and emerges as a promising
field to explain the deranged behavior of microenviron-
ment cells, particularly in tumor progression [149].
Most studies focusing on microenvironment molecular
characterization describe patterns involving the entire
stromal compartment without discriminating alterations
in specific cell types that compose this niche [150]. In
part, this limitation may result from technical difficulties
in efficiently separating different stromal cell types even
in vitro. Isolating immune cells from human solid tumor
samples, for example, is especially challenging [151]. Never-
theless, given the wide functional diversity exhibited by
immune and structural cells during tumor progression
[152–155], molecular screening of individual cell types
in the microenvironment represents a challenge that
cannot be ignored.
Exploiting new targets
The development of cancer therapies started in the 19th
century. Since then, many physical, biological and particu-
larly chemical agents have been used in cancer treatment
[156]. As a result of tumor biology, most therapeuticagents focus on the interruption of malignant growth
through the induction of cell death and/or proliferation
arrest [157]. Traditional anti-carcinogenic agents differ
in their precise mode of action, but in general, they ei-
ther interfere with DNA or with important organelles
involved in cytoskeleton integrity [69]. This overall pat-
tern is represented by the leading approaches in cancer
treatment: chemotherapy and radiotherapy. Since their
development over 50 years ago, these therapies, alone or
in combination, represent the principal line of disease
control and increased survival [157, 158]. Nevertheless,
lack of specificity poses a notorious problem: both healthy
and cancer cells are targeted and the whole organism is
heavily affected (Fig. 2). Furthermore, acquired resistance
to chemotherapeutic agents and to specific target drugs
represents a great challenge concerning cancer treat-
ment [158].
The improvement of DNA-based technologies over the
past decade brought great expectations about the discov-
ery of new molecular targets for selective drugs (Fig. 2)
[159, 160]. Nevertheless, these hopes were in great part
frustrated by the unfortunate association of a range of fac-
tors such as overestimated drug potential and poor know-
ledge of tumor microenvironment [161, 162]. Therapeutic
failure often relates to high mutation rates of tumor cells
and the consequent intratumoral heterogeneity [163]. In a
large number of cases, heterogeneity results from a pecu-
liar nonlinear tumor evolution that stems from important
master mutations and the development of multiple sec-
ondary mutations resulting from the pressure exerted by
environmental factors such hypoxia or even the treatment
itself (Fig. 1) [163, 164].
This complex scenario has elevated the failure rates of
cancer treatments, particularly regarding selective drugs.
These drugs should interact with specific targets that are
frequently altered in malignant cells and do not repre-
sent the entire genetic mosaic of a tumor. This charac-
teristic may partly result from the fact that some drugs
are prescribed from single biopsy studies (Fig. 2) [165].
In other way, some patients with non-small cell lung
cancer become refractory to Epidermal Growth Factor
Receptor (EGFR) inhibitors due to an EGFR mutation or
MET amplification that arises after treatment with Geti-
finib and Erlotinib [166, 167]. Similar results were ob-
served in non-small cell lung cancer patients treated
with the ALK inhibitor Crizotinib. These patients relapse
after the onset of secondary alterations, such as ALK
fusion gene amplification or increased EGF phosphoryl-
ation [168]. Nearly 60 % of melanoma patients harbor
mutations in the BRAF gene. However, BRAF pathway
inhibitors often fail as a result of secondary mutations
to the Platelet-Derived Growth Factor Receptor (PDGFRB)
and NRAS [169]. Moreover, despite the celebrated success
of BCR/ABL fusion gene inhibition in chronic myeloid
Fig. 2 Evolution of cancer therapies over the years. The initial approach represents conventional therapy, which is based on the employment of
unspecific chemical and physical agents (chemo and radiotherapy) that target general cellular processes occurring in both healthy and cancer
cells and that do not take into account molecular alterations exhibited by the tumors. In the second approach, the molecular screening of cancer
cells led to the development of selective drugs based on altered molecular features of malignant cells. This approach is particularly represented
by tyrosine kinase inhibitors and monoclonal antibodies, which specifically target tumor cells. It is based on single-biopsy studies and does not
take into account molecular alterations exhibited by microenvironment (ME) cells or tumor heterogeneity. The current approach shows that, lately,
not only the tumor, but also its ME, have been mapped, which contributed to the development of selective drugs designed for both malignant
and ME cells. The ME alterations more frequently targeted by molecular drugs are the ones observed in several types of cancers, such as angiogenesis,
inflammatory processes and MMP overexpression. Again, this approach is based on single-biopsy studies and does not account for tumor
heterogeneity. The future approach for cancer treatment shall account for the whole molecular heterogeneity, which is differentially exhibited by malignant
and ME cells and unveiled by multiple biopsies
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produces drug resistance via acquisition of novel BCR/
ABL mutations [170] or alternative mechanisms, and the
leukemia stem cells seem to be resistant to BCR/ABL in-
hibitors [171]. Additionally, recent studies have reported
that acquired resistance to some cancer therapies is not
necessarily mediated by malignant cells but by tumor
microenvironment [172]. In fact, provocative resultspublished by Straussman and colleagues showed that ther-
apy resistance exhibited by tumor cell lines that harbor
the BRAF (V600E) mutation was mediated by receptor ac-
tivation (MET) and stromal-cell derived Hepatocyte
Growth Factor (HGF) [173]. Furthermore, it was re-
ported that permanent secretion of proliferation factors
such as WNT16B and the formation of a protective niche
by stroma during treatment comprise one of the main
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175]. In addition to these findings, the role of immune cells
in cancer has been established and their contribution to re-
sistance to traditional and new therapies has been associ-
ated with cellular infiltration patterns [176, 177].
For instance, the presence and function of cells such
as M2 macrophages can impact not only the natural
progression of the tumor, but has also been demonstrated
to impact the tumor response to chemo [73] and radio-
therapy [178], outlining the relevance of characterizing the
presence of these cell populations and ultimately of being
able to manipulate the tumor leucocyte components to
foster the efficacy of the treatment [179].
Presumably, these reports pushed forward the devel-
opment of drugs that target the microenvironment
(Fig. 2), such as metalloproteinase inhibitors (Tanomastat,
Maromastat and Prinomastat), vessel inhibitors (Bevacizu-
mab, Vandetanib, Sunitinib, Axtinib, Sorafenib, and others)
and immune-cell modulators (Aldesleukin, Interferon
Alpha 2b, Sipuleucel T, Ipilimumab, and others). Some
of these therapies have displayed relative clinical success
such as Vascular Endothelial Growth Factor Receptor
(VEGFR)-targeted drugs [180, 181], whereas others, such
as metalloproteinase inhibitors, have exhibited controver-
sial or no results [182].
Immune therapies represent a more complex landscape
due to the fact that the dual roles of the innate and adap-
tive immunological responses have yet to be completely
understood [183]. Nevertheless, some encouraging results
have been reported, especially when immune therapy is
combined with traditional treatments or even with select-
ive drugs [184, 185].
Tumors co-evolve with the immune response avoiding
immune surveillance and ultimately leading to tumor
progression and metastasis [186]. Tumor response to
cytokines produced by leukocytes can lead to the acti-
vation of one of such escape mechanisms, leading to
the impairment of immune response to tumors. This is
the case for instance of the programed death ligand 1
(PDL1) up regulation on tumor cells upon local IFNg
production by infiltrating lymphocytes [187]. The PD1
receptor of recently activated T lymphocytes is engaged
by PDL1 on tumor cells leading to the impairment of T
cell function. This process can be reverted by using
monoclonal antibodies designed to perturb this interaction,
unleashing lymphocytes to exert their antitumor effect
[188], in a clear example of targeted therapy approaching
natural immune mediated antitumor responses. Immune
based antitumor responses can be also induced or
boosted through vaccination approaches [189] or by
simply expanding in vitro tumor specific lymphocytes
to be returned to the patient, a strategy that leads to
massive antitumor responses in a fraction of patients
bearing metastatic melanomas [190]. A more refinedderivation of this approach includes cloning and trans-
genically transferring T cell receptors to T lymphocytes
[191] or chimeric antigen receptors (CARs) [192, 193]
specific for tumor antigens. These strategies have proven
able to induce tumor remissions in hematopoietic tumors,
especially for CAR utilization in CD19+ target tumors
[194] and will likely prove efficient also in solid tumors
[192, 195]. The recent resultsobtained by several groups
prove again the huge potential of understanding the basic
mechanisms underlying the immune evasion by tumors
and the best maneuvers to tackle these processes, leading
to tumor elimination.
Research on the tumor microenvironment as a target
for cancer therapy has only just begun when compared
with research on tumor cell targets, and, therefore, the
benefits of this approach are not yet clear. The future
development of new drugs, which will take into account
cancer cells and their microenvironment (Fig. 2), is needed
and depends on a better understanding of stromal biology,
anchored on morphological, phenotypic and genomic
studies. Considering the concepts and ideas exposed in
this review, it is reasonable to consider the microenvir-
onment as a formidable opportunity for the development
of new selective drugs since these cells provide an ex-
citing potential target that may exhibit lower mutation
rates than malignant cells.
Conclusion
Genetic determinism has dominated cancer research and
produced invaluable insights. However, the simplistic som-
atic mutation theory (SMT), which states that genetic in-
stability of malignant cells alone drives disease progression,
has proved insufficient to explain tumor behavior and,
consequently, to point to new disease therapies. A recent,
more dynamic view of tumors suggests that disease pro-
gression is promoted by the orchestrated interaction be-
tween malignant cells and their surrounding environment.
Therefore, the development of more effective new therap-
ies requires a global view that integrates the genocentric
and microenvironmental knowledge in a plural approach.
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